Regular Article
Expression and Characterization of Human Recombinant and α-N-Actylglucosaminidase

https://doi.org/10.1006/prep.2000.1361Get rights and content

Abstract

Mucopolysaccharidosis type IIIB (MPS-IIIB, Sanfilippo type B Syndrome) is a heterosomal, recessive lysosomal storage disorder resulting from a deficiency of [alpha]-N-acetylglucosaminidase (NAGLU). To characterize this enzyme further and evaluate its potential for enzyme replacement studies we expressed the NAGLU-encoding cDNA in Chinese hamster ovary cells (CHO-K1 cells) and purified the recombinant enzyme from the medium of stably transfected cells by a two-step affinity chromatography. Two isoforms of recombinant NAGLU with apparent molecular weights of 89 and 79 kDa were purified and shown to differ in their glycosylation pattern. The catalytic parameters of both forms of the recombinant enzyme were indistinguishable from each other and similar to those of NAGLU purified from various tissues. However, compared to other recombinant lysosomal enzymes expressed from CHO-K1 cells, the mannose-6-phosphate receptor mediated uptake of the secreted form of recombinant NAGLU into cultured skin fibroblasts was considerably reduced. A small amount of phosphorylated NAGLU present in purified enzyme preparations was shown to be endocytosed by MPS-IIIB fibroblasts via the mannose-6-phosphate receptor-mediated pathway and transported to the lysosomes, where they corrected the storage phenotype. Direct metabolic labeling experiments with Na232PO4 confirmed that the specific phosphorylation of recombinant NAGLU secreted from transfected CHO cells is significantly lower when compared with a control lysosomal enzyme. These results suggest that the use of secreted NAGLU in future enzyme and gene replacement therapy protocols will be severely limited due to its small degree of mannose-6-phosphorylation.

References (39)

  • P.J. Meikle et al.

    Prevalence of lysosomal storage disorders

    JAMA

    (1999)
  • E. Neufeld et al.
  • J.J. Hopwood et al.

    The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment

    Mol. Biol. Med.

    (1990)
  • K. von Figura et al.

    Biosynthesis and maturation of alpha-N-acetylglucosaminidase in normal and Sanfilippo B-fibroblasts

    Am. J. Hum. Genet.

    (1984)
  • P. Di Natale et al.

    Biosynthesis of alpha-N-acetylglucosaminidase in cultured human kidney carcinoma cells

    Enzyme

    (1985)
  • D. Salvatore et al.

    Biosynthesis of alpha-N-acetylglucosaminidase in human kidney cells

    Biol. Cell

    (1982)
  • D. Salvatore et al.

    Lysosomal alpha-N-acetylglucosaminidase: Purification and characterisation of the human urinary enzyme

    Bull. Mol. Biol. Med.

    (1984)
  • T. Sasaki et al.

    Purification and partial characterization of alpha-N-acetylglucosaminidase from human liver

    J. Biochem. (Tokyo)

    (1991)
  • B. Weber et al.

    Cloning and expression of the gene involved in Sanfilippo B syndrome (mucopolysaccharidosis III B)

    Hum. Mol. Genet.

    (1996)
  • Cited by (34)

    • Brain transplantation of genetically corrected Sanfilippo type B neural stem cells induces partial cross-correction of the disease

      2022, Molecular Therapy Methods and Clinical Development
      Citation Excerpt :

      To date, intra-cerebroventricular (ICV) enzyme replacement therapy (ERT),9 gene therapy,10 hematopoietic stem cell gene therapy,11 and substrate reduction12 have all been explored in preclinical studies as potential treatments for this disease. Although systemic ERT has shown promise in promoting functional recovery in MPS subtypes known to induce moderate neurological impairment (MPS I,13 II,14 IVA,15 and VII16), it poorly impacted both neurological deficit and cellular uptake in Sanfilippo type B17 because the recombinant human NAGLU (rhNAGLU) does not cross the blood-brain barrier.18 Currently, there is one ERT-based clinical trial (NCT03784287) testing the effect of the ICV implantation of an infusion port for direct delivery of the NAGLU enzyme to the brain.

    • Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins

      2022, Advanced Drug Delivery Reviews
      Citation Excerpt :

      M6P is incorporated in nearly all of the lysosomal enzymes, including IDUA, IDS, ASA, SGSH, PPT1, GLB1, ASM, and HEXA [4]. Although NAGLU is predicted to incorporate M6P [4], the M6P content of this enzyme is very low [192,193]. Despite the lack of M6P incorporation into NAGLU, this enzyme is still rapidly cleared from plasma following IV administration in the mouse [194].

    • Update of treatment for mucopolysaccharidosis type III (sanfilippo syndrome)

      2020, European Journal of Pharmacology
      Citation Excerpt :

      Positive results gave manufacture confidence to set up clinical trials for testing SOBI003 as a potential treatment for MPS IIIA patients (NCT03423186 & NCT03811028). Chinese hamster ovary cells or a human cell line could not generate recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with mannose 6-phosphate during post-translational processing, so rhNAGLU for MPS IIIB patients is limited by inadequate cellular delivery (Weber et al., 2001; Zhao and Neufeld, 2000). BMN 250 is a fusion protein, consisting of human NAGLU fused with insulin-like growth factor 2 (IGF2), which was expressed in Chinese hamster ovary cells (Fig. 1B) (Aoyagi-Scharber et al., 2017).

    • Lysosomal N-acetyltransferase interacts with ALIX and is detected in extracellular vesicles

      2018, Biochimica et Biophysica Acta - Molecular Cell Research
      Citation Excerpt :

      Not only could this provide a point of interaction between NAGLU and ALIX, but also raises the tantalising prospect of an association between HGSNAT and NAGLU via ALIX, a co-localisation which would provide a kinetic advantage for the HS hydrolysis, and its mediation of exosome biogenesis. Furthermore, both the mannose 6-phosphorylation of NAGLU, and its mannose 6-phosphate-mediated transport, have been reported to be relatively inefficient, so an HGSNAT/NAGLU containing complex may contribute to extracellular transport of NAGLU [54]. A problem for MPS IIIC, and indeed all disorders caused by deficiencies of insoluble, multi-pass transmembrane proteins, is that those approaches used to rescue soluble protein deficiencies (such as receptor-mediated enzyme replacement therapy, and extensions of this, including gene therapy) are not applicable.

    View all citing articles on Scopus
    1

    Both authors contributed equally to this paper.

    2

    To whom correspondence should be addressed. Fax: 61 8 8204 7100. E-mail: [email protected].

    View full text